Interactions among α-synuclein, dopamine, and biomembranes: Some clues for understanding neurodegeneration in Parkinson's disease

Journal of Molecular Neuroscience

Volumn 23, Issue 1-2, 2004, Pages 23-33

  Rochet, Jean Christophe ^a,c   Outeiro, Tiago Fleming ^b   Conway, Kelly A ^a,d   Ding, Tomas T ^a   Volles, Michael J ^a   Lashuel, Hilal A ^a   Bieganski, Robert M ^a   Lindquist, Susan L ^b   Lansbury Jr , Peter J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c PURDUE UNIVERSITY   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dopamine; Fibril; Membrane; Parkinson's disease; Protofibril; Synuclein; Yeast

Indexed keywords

ALPHA SYNUCLEIN; CATECHOLAMINE; DOPAMINE; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

ATOMIC FORCE MICROSCOPY; BETA SHEET; BINDING AFFINITY; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; FIBER; MEMBRANE; MEMBRANE BINDING; MEMBRANE PERMEABILITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; TRANSGENIC ANIMAL; YEAST; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE; GENETICS; HUMAN; METABOLISM; NERVE CELL; NEUROFILAMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN BINDING;

ANIMALIA;

ALPHA-SYNUCLEIN; ANIMALS; CELL MEMBRANE; DOPAMINE; HUMANS; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NEUROFIBRILS; NEURONS; PARKINSON DISEASE; PROTEIN BINDING; SYNUCLEINS;

EID: 4344641972     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:23:1-2:023     Document Type: Review

References (55)

1. Arima K., Ueda K., Sunohara N., Arakawa K., Hirai S., Nakamura M., et al. (1998) NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. (Berl.) 96, 439-444.
2. Baba M., Nakajo S., Tu P.- H., Tomita T., Nakaya K., Lee V. M.- Y., et al. (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
3. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
4. Bussell R. and Eliezer D. (2003) Astructural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 329, 763-778.
5. Chandra S., Chen X., Rizo J., Jahn R., and Sudhof T. C. (2003) A broken α-helix in folded α-synuclein. J. Biol. Chem. 278, 15313-15318.
6. Chernoff Y. O., Uptain S. M., and Lindquist S. L. (2002) Analysis of prionfactors in yeast. Methods Enzymol. 351, 499-538.
7. Clayton D. F. and George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129.
8. Cole N. B., Murphy D. D., Grider T., Rueter S., Brasaemle D., and Nussbaum R. L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-synuclein. J. Biol. Chem. 277, 6344-6352.
9. Conway K. A., Harper J. D., and Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
10. Conway K. A., Harper J. D., and Lansbury P. T., Jr. (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
11. Conway K. A., Rochet J.-C., Bieganski R. M., and Lansbury P. T., Jr. (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349.
12. Davidson W. S., Jonas A., Clayton D. F., and George J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
13. Dawson T. M. and Dawson V. L. (2002) Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. Suppl. 5, 1058-1061.
14. Ding T. T., Lee S.- J., Rochet J.- C , and Lansbury P. T., Jr. (2002) Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209-10217.
15. Dunnett S. B. and Bjorklund A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature (Suppl.)399, A32-A39.
16. El-Agnaf O. M., Jakes R., Curran M. D , and Wallace A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70.
17. Eliezer D., Kutluay E., Bussell R., Jr., and Browne G. (2001) Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073.
18. Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
19. Forno L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272.
20. Giasson B. I., Murray I. V., Trojanowski J. Q., and Lee V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386.
21. Giasson B. I., Uryu K., Trojanowski J. Q., and Lee V. M.-Y. (1999) Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622.
22. Harper J. D., Lieber C. M., and Lansbury P. T., Jr. (1997a) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β-protein. Chem. Biol. 4, 951-959.
23. Harper J. D., Wong S. S., Lieber C. M., and Lansbury P. T., Jr. (1997b) Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125.
24. Hashimoto M., Hsu L. J., Sisk A., Xia Y., Takeda A., Sundsmo M., and Masliah E. (1998) Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799, 301-306.
25. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva, H. A., et al. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
26. Jakes R., Spillantini M. G., and Goedert M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32.
27. Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G., and Goedert M. (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292-26294.
28. Jo E., Fuller N., Rand R. P., St. George-Hyslop P., and Fraser P. E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein. J. Mol. Biol. 315, 799-807.
29. Jo E., McLaurin J., Yip C. M., St. George-Hyslop P., and Fraser P. E. (2000) α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328-34334.
30. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
31. Kruger R., Kühn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
32. Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T., and Lansbury P. T., Jr. (2002) α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102.
33. Lee H.-J., Choi C., and Lee S.-J. (2002) Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678.
34. Li J., Uversky V. N., and Fink A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 40, 11604-11613.
35. Li J., Uversky V. N., and Fink A. L. (2002) Conformational behavior of human α-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23, 553-567.
36. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H. K., and Brundin P. (2002) Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894.
37. Maroteaux L., Campanelli J. T., and Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815.
38. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., et al. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
39. Narhi L., Wood S. J., Steavenson S., Jiang Y., Wu G. M., Anafi D., et al. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
40. Orth M. and Schapira A. H. (2002) Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40, 533-541.
41. Outeiro T. F., Lindquist S. (2003) Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302, 1772-1775.
42. Perrin R. J., Woods W. S., Clayton D. F., and George J. M. (2000) Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34393-34398.
43. Pollanen M. S., Dickson D. W., and Bergeron C. (1993) Pathology and biology of the Lewy body. J. Neuropath. Exp. Neurol. 52, 183-191.
44. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
45. Sherer T. B., Betarbet R., and Greenamyre J. T. (2002) Environment, mitochondria, and Parkinson's disease. Neuroscientist 8, 192-197.
46. Sherer T. B., Kim J. H., Betarbet R., and Greenamyre J. T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp. Neurol. 179, 9-16.
47. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., and Goedert M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473.
48. Spillantini M. G., Schmidt M. L., Lee V. M.-Y., Trojanowski J. Q., Jakes R., and Goedert M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840.
49. Takahashi H. and Wakabayashi K. (2001). The cellular pathology of Parkinson's disease. Neuropathology 21, 315-322.
50. Tompkins M. M. and Hill W. D. (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res. 775, 24-29.
51. van Duinen S. G., Lammers G. J., Maat-Schieman M. L., and Roos R. A. (1999) Numerous and wide-spread α-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol. (Berl.) 97, 533-539.
52. Volles M. J., Lee S.-J., Rochet J.-C., Shtilerman M. D., Ding T. T., Kessler J. C., and Lansbury P. T., Jr. (2001) Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
53. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., and Takahashi H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239, 45-48.
54. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., and Teplow D. B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372.
55. Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and Lansbury P. T., Jr. (1996) NACP, a protein implicated in Alzheimer 's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.